Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Tamara Y. Milder"'
Publikováno v:
Drug Safety
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a major advance in the fields of diabetology, nephrology, and cardiology. The cardiovascular and renal benefits of SGLT2 inhibitors are likely largely independent of their glycaemic effects, and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1542788360674d7bd77adedbe359f6ed
https://doi.org/10.1007/s40264-020-01010-6
https://doi.org/10.1007/s40264-020-01010-6
Autor:
Richard O. Day, Jerry R. Greenfield, Tamara Y. Milder, Sophie L. Stocker, Dorit Samocha-Bonet
Publikováno v:
European Journal of Clinical Pharmacology. 75:1481-1490
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal disease. These benefits are seen in patients with impaired rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::673d5f581b1eb8ccb5916649e5a6d015
https://doi.org/10.1007/s00228-019-02732-y
https://doi.org/10.1007/s00228-019-02732-y
Publikováno v:
Diabetes. 70
Aims: To explore: 1) Primary Care Physicians’ (PCPs) perspectives regarding initiating SGLT2 inhibitors (SGLT2i) in patients with type 2 diabetes and their current and preferred sources of education about SGLT2i and type 2 diabetes pharmacotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2428af8eabd2e741ce3fb51e7f364d84
https://doi.org/10.2337/db21-779-p
https://doi.org/10.2337/db21-779-p
Publikováno v:
Anaesthesia. 73:1008-1018
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an emerging class of oral hypoglycaemic agents with therapeutic benefits beyond better glycaemic control. A major concern of the sodium-glucose co-transporter 2 inhibitors is their propensity to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1555e3b6fabed09b6319f3aa17af26d
https://doi.org/10.1111/anae.14251
https://doi.org/10.1111/anae.14251
Publikováno v:
Diabetes Research and Clinical Practice. 180:109036
Aims To explore: 1) General Practitioners’ (GPs’) perspectives regarding initiating SGLT2 inhibitors and the resources that inform their pharmacotherapy choices; and 2) The support provided to GPs by Endocrinologists in relation to the prescripti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7cf3a1631df4780eadbe58908aa8790
https://doi.org/10.1016/j.diabres.2021.109036
https://doi.org/10.1016/j.diabres.2021.109036
Publikováno v:
Internal medicine journal. 50(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2651e53d8694346a51eff6875b3a70f
https://pubmed.ncbi.nlm.nih.gov/32431044
https://pubmed.ncbi.nlm.nih.gov/32431044
Autor:
Tamara Y, Milder, Sophie L, Stocker, Dorit, Samocha-Bonet, Richard O, Day, Jerry R, Greenfield
Publikováno v:
European journal of clinical pharmacology. 75(11)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal disease. These benefits are seen in patients with impaired rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1452bece79b6c7459515102216d0486
https://pubmed.ncbi.nlm.nih.gov/31377891
https://pubmed.ncbi.nlm.nih.gov/31377891
Autor:
Lucy McGrath-Cadell, Dorit Samocha-Bonet, Tamara Y. Milder, Christina Abdel Shaheed, Richard O. Day, Sophie L. Stocker, Jerry R. Greenfield
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 8, Iss 1, p 45 (2019)
Journal of Clinical Medicine, Vol 8, Iss 1, p 45 (2019)
Background: Guidelines differ with regard to indications for initial combination pharmacotherapy for type 2 diabetes. Aims: To compare the efficacy and safety of (i) sodium-glucose cotransporter 2 (SGLT2) inhibitor combination therapy in treatment-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a444ce990464bd44724a413cf6558d0
https://pubmed.ncbi.nlm.nih.gov/30621212
https://pubmed.ncbi.nlm.nih.gov/30621212
Autor:
Deborah Marriott, Brendan McMullan, John Harkness, Louise Killen, Melissa T. Baysari, Vincent Lam, Anthony Minh Tien Chau, Richard O. Day, Tamara Y. Milder, Jonathan Brett
Publikováno v:
Journal of Pharmacy Practice and Research. 43:97-100
Aim: To evaluate the use of pneumonia severity scores for diagnosing community-acquired pneumonia (CAP) and to assess whether antibiotic prescribing was compliant with guidelines as determined by the calculated pneumonia severity score. Method: A ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72e2c47b27d68bd33f83eac24c711cea
https://doi.org/10.1002/j.2055-2335.2013.tb00228.x
https://doi.org/10.1002/j.2055-2335.2013.tb00228.x
Objective: To explore the key motivators behind selection of analgesics (non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol and complementary medications (CMs)) by patients with osteoarthritis (OA). Methods: A qualitative study, in which in-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35614db59f6e17eeeabab2cc6eba9863
https://hdl.handle.net/2123/11713
https://hdl.handle.net/2123/11713
